| アブストラクト | BACKGROUND: beta-blockers (beta-adrenoceptor antagonists), commonly used for cardiovascular conditions, may be linked to neuropsychiatric adverse events (AEs). However, many prevalent ones, including delirium and hallucinations, remain insufficiently studied. AIMS: To compare the neuropsychiatric risks of beta-blockers with other antihypertensive drugs using data from the FDA Adverse Event Reporting System (FAERS) and differences between lipophilic and hydrophilic beta-blockers. METHOD: An active-comparator restricted disproportionality analysis was conducted using data from the FAERS (2004Q1-2023Q4). Neuropsychiatric AEs were analyzed using Preferred Terms and the System Organ Classes from the Medical Dictionary for Regulatory Activities for beta-blockers compared to lisinopril and losartan. Adjusted Reporting Odds Ratios (aRORs) were calculated using logistic regression to account for potential confounders. RESULTS: beta-blockers were linked to a significantly higher risk of nervous and psychiatric disorders, compared to lisinopril and losartan. Among the nine types of neuropsychiatric events studied, six-dizziness, nightmares, insomnia, hallucinations, somnolence, and disorientation-showed higher aRORs with beta-blockers. Propranolol, a lipophilic beta-blocker, exhibited the highest aRORs for psychiatric disorders and six types of neuropsychiatric events, including nightmares, delirium, hallucinations, disorientation, altered mental status, and somnolence, compared to lisinopril and losartan. Compared to atenolol, propranolol remained significantly associated with delirium, hallucinations, and disorientation. CONCLUSION: beta-blockers, especially propranolol, may be associated with a higher risk of neuropsychiatric AEs compared to lisinopril and losartan. These findings highlight the importance of considering the specific beta-blocker prescribed, particularly in patients at risk for central nervous system side effects. Further population-based studies are warranted to confirm these results. |
|---|
| ジャーナル名 | Journal of psychopharmacology (Oxford, England) |
|---|
| Pubmed追加日 | 2025/7/24 |
|---|
| 投稿者 | Ez Eddin, Lujain; Omrani, Mohammad Ali; Chalabianloo, Niaz; Muanda, Flory T |
|---|
| 組織名 | ICES Western, London, ON, Canada.;Department of Physiology and Pharmacology, Western University, London, ON,;Canada.;Department of Computer Science, Western University, London, ON, Canada.;Department of Epidemiology and Biostatistics, Western University, London, ON,;Lawson Health Research Institute, London Health Sciences Center, London, ON, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40704576/ |
|---|
